Study reveals potential new strategy for managing inflammatory bowel disease
Celltrion unveils promising dose escalation results for subcutaneous infliximab
Related Posts
Roche partners with Cardiff researchers to uncover new research into dementia
Affecting 55 million people globally, dementia impairs the ability to remember, think or make decisions Roche and the Cardiff University Brain Research Imaging Centre (CUBRIC) […]
UK sees 70% increase in phase I advanced therapy clinical trials in 2024
Cell and Gene Therapy Catapult reveals significant growth in UK trials The UK experienced a notable increase in advanced therapy clinical trials in 2024, reaching […]
Eisai data shows sustained benefit of lecanemab in early Alzheimer’s disease
Four-year treatment slows cognitive decline with consistent safety profile Eisai has presented new clinical data showing that patients with early Alzheimer’s disease continue to benefit […]